3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Wilms Tumor
2
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Uveal Melanoma
1
Pancreatic Neoplasms
1
Neoplasms
1
Myelodysplastic Syndromes
1
Leukemia, Myeloid, Acute
1
Histiocytic Sarcoma
1
Gastrointestinal Neoplasms
1
Central Nervous System Neoplasms
1
Advanced Solid Tumors
1
Advanced Solid Tumor
1
Interventions
Sunitinib
64
Nivolumab
42
pembrolizumab
36
Bevacizumab
32
Everolimus
31
Sorafenib
25
pazopanib
23
Axitinib
23
cabozantinib
14
aldesleukin
13
Ipilimumab
13
temsirolimus
11
Interferon alpha-2
11
Cyclophosphamide
10
avelumab
9
Magnetic Resonance Spectroscopy
9
Interleukin-2
9
lenvatinib
8
atezolizumab
8
Radiosurgery
8
Gemcitabine
8
Immunoglobulin G
7
Erlotinib Hydrochloride
7
Disulfides
6
fludarabine phosphate
5
Radiotherapy
5
Fluorodeoxyglucose F18
5
peginterferon alfa-2b
4
Vorinostat
4
Tyrosine Kinase Inhibitors
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Renal Cell
×
ulixertinib
×
Clear all
No trials found.